Floatz logo

Cyclophosphamide

BRAF V600 Mutation

UNICANCERSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

19 Active assets in the BRAF V600 Mutation cohort.

Asset / SponsorPhaseRating
Binimetinib
UNICANCER
Phase 2BB
Encorafenib
UNICANCER
Phase 2B
Nivolumab
H. Lee Moffitt Cancer Center and Research Institute
Phase 2B
Cobimetinib
ABM Therapeutics Corporation
Phase 2B
gsk1120212
Xynomic Pharmaceuticals, Inc.
Phase 2B

View all 21 →

Same molecule, other indications

Cyclophosphamide is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
mycosis fungoidesDormant
BBB
Indicative ·
78 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →